Cite
HARVARD Citation
Imai, H. et al. (2021). Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer. Thoracic cancer. 12 (8), pp. 1171-1179. [Online].